iPSC-derived anti-BCMA CAR-T cell therapy (Fate Therapeutics/Max-Delbruck-Center for Molecular Medicine)

N/A

Report date: 2025/06/11 10:46:39

Base Information

Drug NameiPSC-derived anti-BCMA CAR-T cell therapy (Fate Therapeutics/Max-Delbruck-Center for Molecular Medicine)
Drug Alias NameCAR-BCMA + hnCD16 + TRAC + CD38-KO CAR-iT cell therapy (Fate Therapeutics/Max-Delbruck-Center for Molecular Medicine)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulantsTumor necrosis factor ligand superfamily member 13 modulators
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMax Delbruck Centrum Fur Molekulare MedizinFate Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A